Background
Methods
Protocol
Umbrella review of systematic reviews (with/without meta-analyses) of risk factors
Literature search and eligibility criteria
Data extraction
Evidence synthesis and evaluation
Sensitivity analysis
Comparative cross-assessment of risk factors and risk prediction models
Results
Literature review
Meta-analyses of risk factors for CRC metastasis
Population | Outcome | Risk factor | Risk factor prevalence | Effect size (95% CI) | Evidence classification |
---|---|---|---|---|---|
Histopathological risk factor | |||||
pT1 CRC | Lymph node metastasis in pT1 CRC | Vascular invasion | 330/1731 = 19% | 2.73 (1.98–3.78) | Convincing |
pT1 CRC | Lymph node metastasis in pT1 CRC | Lymphatic invasion | 906/3347 = 27% | 6.78 (5.29–8.69) | Highly suggestive |
pT1 CRC | Lymph node metastasis in pT1 CRC | Tumor budding | 2401/10,128 = 24% | 6.39 (5.23–7.80) | Highly suggestive |
CRC | Lymph node metastasis in CRC | Tumor budding | 1955/6739 = 29% | 4.96 (3.97–6.19) | Highly suggestive |
Rectal cancer | Lymph node metastasis in rectal cancer | Tumor size > 1 cm | 203/348 = 58% | 6.76 (3.25–14.04) | Highly suggestive |
pT1 CRC | Lymph node metastasis in pT1 CRC | Lymphovascular invasion | 340/1695 = 20% | 4.81 (3.14–7.36) | Suggestive |
pT1 CRC | Lymph node metastasis in pT1 CRC patients who underwent additional surgeries after an endoscopic resection | Lymphovascular invasion | 91/313 = 29% | 5.29 (2.34–11.98) | Suggestive |
pT1 CRC | Lymph node metastasis in pT1 CRC | Poor differentiation | 94/2722 = 4% | 5.61 (2.90–10.83) | Suggestive |
Rectal cancer | Lymph node metastasis in rectal cancer | Muscularis properia invasion | 122/322 = 38% | 5.08 (2.32–11.11) | Suggestive |
pT1 CRC | Lymph node metastasis in pT1 CRC | Submucosal invasion ≥ 1 mm | 2389/2922 = 82% | 2.95 (1.39–6.27) | Weak |
Small rectal NETs | Lymph node metastasis in small rectal NETs treated by local excision | Lymphovascular invasion | 104/517 = 20% | 5.02 (1.16–21.72) | Weak |
Rectal cancer | Lymph node metastasis in rectal cancer | Central depression | 32/76 = 42% | 3.00 (2.10–4.28) | Weak |
Rectal cancer | Synchronous metastasis in rectal cancer | MRI-detected extramural vascular invasion (mrEMVI) | 212/804 = 26% | 5.65 (2.12–15.05) | Weak |
Small rectal NETs | Lymph node metastasis in small rectal NETs treated by local excision | Lymphatic invasion | 73/493 = 15% | 5.54 (0.02–1752.46) | No association |
Rectal cancer | Lymph node metastasis in rectal cancer | Vascular invasion | 46/168 = 27% | 5.86 (0.77–44.62) | No association |
Small rectal NETs | Lymph node metastasis in small rectal NETs treated by local excision | Vascular invasion | 75/211 = 36% | 3.63 (0.05–268.57) | No association |
pT1 CRC | Lymph node metastasis in pT1 CRC patients who underwent additional surgeries after an endoscopic resection | Poor or moderate differentiation | 122/209 = 58% | 3.77 (1.12–123.16) | No association |
Biomarker | |||||
CRC | Lymph node metastasis in CRC | Downregulated E-cadherin expression | 829/1573 = 53% | 0.49 (0.34–0.72) | Highly suggestive |
CRC | Hepatic metastasis (distant) in CRC | Circulating tumor cells | 103/310 = 33% | 6.38 (2.67–15.26) | Suggestive |
CRC | Lymph node metastasis in CRC | Low MUC2 expression level | 613/1335 = 46% | 1.42 (1.19–1.69) | Suggestive |
CRC | Distant metastasis in CRC | Downregulated E-cadherin expression | 509/1027 = 50% | 0.45 (0.23–0.91) | Weak |
CRC | Lymph node metastasis in CRC | Circulating tumor cells | 797/1802 = 44% | 1.62 (1.17–2.23) | Weak |
CRC | Lymph node metastasis in CRC | p16 protein expression | 482/800 = 60% | 0.50 (0.30–0.84) | Weak |
CRC | Distant metastasis in CRC | Cyclin D1 overexpression | 952/1515 = 63% | 0.60 (0.36–0.99) | Weak |
CRC | Distant metastasis in CRC | β-catenin overexpression in the nucleus | 283/531 = 53% | 0.48 (0.29–0.79) | Weak |
CRC | Lymph node metastasis in CRC | CD147 expression | 603/815 = 74% | 1.41 (0.39–5.01) | No association |
CRC | Distant metastasis in CRC | CD147 expression | 405/538 = 75% | 2.32 (1.34E−06 to 4.03E+06) | No association |
CRC | Lymph node metastasis in CRC | CD133 expression | 550/1629 = 34% | 1.15 (0.82–1.62) | No association |
CRC | Distant metastasis in CRC | CD133 expression | 300/1064 = 28% | 1.54 (0.39–6.09) | No association |
CRC | Lymph node metastasis in CRC | HER-2 immunohistochemical expression | 440/1289 = 34% | 1.90 (0.90–4.02) | No association |
Genetic risk factor | |||||
CRC | Lymph node metastasis in CRC | BRAF mutation | 736/1142 = 64% | 0.75 (0.49–1.14) | No association |
CRC | Lymph node metastasis in CRC | RASSF1A promoter methylation | 100/184 = 54% | 1.61 (0.16–16.16) | No association |
CRC | Distant metastasis in CRC | RASSF1A promoter methylation | 153/417 = 37% | 2.57 (0.64–10.24) | No association |
Demographic risk factor | |||||
pT1 CRC | Lymph node metastasis in pT1 CRC | Female gender | 465/1329 = 35% | 2.23 (0.78–6.42) | No association |
Meta-analyses of risk factors for CRC recurrence
Population | Outcome | Risk factor | Risk factor prevalence | Effect size (95% CI) | Evidence classification |
---|---|---|---|---|---|
Histopathological risk factor | |||||
CRC | Overall recurrence in CRC | Tumor budding | 802/2773 = 29% | 5.50 (3.65–8.29) | Highly suggestive |
CRC | Overall recurrence in CRC | Extranodal extension (ENE) | 376/877 = 43% | 2.07 (1.65–2.61) | Highly suggestive |
Rectal cancer | Local recurrence in rectal cancer | Perineural invasion (PNI) | 336/1700 = 20% | 3.21 (2.33–4.44) | Highly suggestive |
Rectal cancer | Distant metastatic recurrence in rectal cancer | MRI-detected extramural vascular invasion (mrEMVI) | 350/1262 = 28% | 3.91 (2.61–5.86) | Highly suggestive |
CRC | Local recurrence in CRC | Intramural vascular invasion (IMVI) | 137/503 = 27% | 1.55 (0.11–21.28) | No association |
Biomarker | |||||
CRC | Overall recurrence in CRC | Absence of peritoneal free tumor cells in pre-resection | 524/593 = 88% | 0.38 (0.16–0.91) | Weak |
CRC | Overall recurrence in CRC | Absence of peritoneal free tumor cells in post-resection | 214/252 = 85% | 0.07 (0.02–0.21) | Weak |
Genetic risk factor | |||||
CRC | Overall recurrence in CRC | PTGS2 (also known as COX-2) | 787/1516 = 52% | 2.78 (1.76–4.40) | Suggestive |
Clinical risk factor | |||||
CRC | Local recurrence in CRC | Anastomotic leakage (AL) | 3929/39,745 = 10% | 1.90 (1.48–2.43) | Suggestive |
Rectal cancer | Local recurrence in rectal cancer | Anastomotic leakage (AL) | 1300/13,665 = 10% | 1.61 (1.25–2.08) | Suggestive |
CRC | Distant recurrence in CRC | Anastomotic leakage (AL) | 865/10,392 = 8% | 1.20 (0.94–1.52) | No association |
Rectal cancer | Distant recurrence in rectal cancer | Anastomotic leakage (AL) | 566/5221 = 11% | 1.06 (0.72–1.58) | No association |
Colon cancer | Local recurrence in colon cancer | Anastomotic leakage (AL) | 91/1990 = 5% | 2.19 (0.55–8.68) | No association |
Comorbidity | |||||
CRC | Overall recurrence in CRC | Diabetes | 429/4979 = 9% | 1.26 (0.70–2.30) | No association |
Anthropometric indices | |||||
CRC | Overall recurrence in CRC | Underweight | 2752/17,636 = 16% | 1.13 (1.05–1.21) | Weak |
CRC | Overall recurrence in CRC | Obese | 6362/21,246 = 30% | 1.07 (1.02–1.13) | Weak |
CRC | Overall recurrence in CRC | Overweight | 13,225/28,109 = 47% | 1.00 (0.96–1.05) | No association |
Methodological quality and risk of bias assessment
Sensitivity analysis of redefying the disease outcome groups
Comparative cross-assessment between risk factors evaluated in the umbrella review and risk predictors applied in existing prediction models
Prediction models for CRC metastasis
Author, year | Country | Study design | Population | Outcome | Prediction time horizon | Sample size (development/validation) | Predictors | Model performance (95%CI) | Model presentation | Internal validation |
---|---|---|---|---|---|---|---|---|---|---|
*Macias-Garcia, 2015 [22] | Spain | D | Submucosal invasive (T1) CRC | Lymph node metastasis | NA | 97 | Sessile morphology | AUC 0.90 (0.81–0.99) | Risk score | NA |
Tumor differentiation | ||||||||||
Infiltrative growth pattern | ||||||||||
Lymphoid infiltrate | ||||||||||
Taylor, 1990 [23] | UK | D | CRC | Liver metastasis | 10 years | 134 | Sex | Sensitivity 0.74, specificity 0.62 | Formula | NA |
ALP | ||||||||||
Dukes B | ||||||||||
Dukes C | ||||||||||
Segelman, 2014 [24] | Sweden | D + IV | CRC (I–III) | Peritoneal metastasis | 3 years | colon 5348/rectal 2696 | Age | C statistic: colon 0.80, rectal 0.78; calibration plot | Calculator | Bootstrapping |
Cancer location | ||||||||||
pT stage | ||||||||||
pN stage | ||||||||||
No. of lymph nodes examined | ||||||||||
Preoperative radiotherapy radicality | ||||||||||
Type of surgery | ||||||||||
Adjuvant chemotherapy | ||||||||||
*Huang, 2016 [25] | China | D + IV | CRC | Lymph node metastasis | NA | 266/60 | Radiomics signature | C statistic 0.736 (0.759–0.766); Hosmer–Lemeshow test: p = 0.916 | Nomogram | Random split |
CEA | ||||||||||
CT-reported LN status | ||||||||||
*Hu, 2019 [26] | China | D + IV | CRC patients with indeterminate pulmonary nodules | Lung metastasis | NA | 136/58 | Chronicity (synchronous nodule or metachronous lesion) | AUC 0.929 (0.885–0.974); calibration plot | Nomogram | Random split |
Rad-score | ||||||||||
pN stage | ||||||||||
*Xu, 2019 [27] | China | D + IV | CRC | Synchronous bone metastasis | NA | 41,902/13,967 | Cancer location | AUC 0.903; sensitivity 0.851; specificity 0.845 | Risk score | Random split |
Tumor differentiation | ||||||||||
Cancer histological type | ||||||||||
CEA | ||||||||||
pN stage | ||||||||||
Brain metastasis | ||||||||||
Liver metastasis | ||||||||||
Lung metastasis | ||||||||||
*JR, 2019 [28] | Korea | D + EV | Submucosal invasive (T1) CRC | Lymph node metastasis | NA | 833/722 | Histologic grade | AUC 0.812 (0.770–0.855); Hosmer–Lemeshow test: p = 0.737 | Nomogram | NA |
Submucosal invasion | ||||||||||
Vascular invasion | ||||||||||
Tumor budding | ||||||||||
Beumer, 2014 [29] | Netherlands | D + EV | CRC | Distant metastasis | 5 years | 50/43 | MiR25/miR339 | AUC 0.80 (0.67–0.93); calibration plot | Nomogram | NA |
AJCC stage | ||||||||||
Age at surgery | ||||||||||
Sex | ||||||||||
*Wang, 2017 [30] | China | D | Colon cancer | Peritoneal metastasis | NA | 1417 | Age | ROC 0.753 | Nomogram | NA |
pT stage | ||||||||||
Lesion not traversable | ||||||||||
Infiltrative growth pattern | ||||||||||
Tumor size | ||||||||||
CEA | ||||||||||
Histopathologic type of mucinous or signet ring cell adenocarcinoma | ||||||||||
Gijn, 2015 [31] | Netherlands | D + IV | Rectal cancer (tis–III) | Metastasis | 5 years | 2172 | Distance from the anal verge | C statistic 0.761 (0.740–0.784); Hosmer–Lemeshow test: p = 0.82 | Nomogram | Cross-validation |
pT stage | ||||||||||
pA stage | ||||||||||
pN stage | ||||||||||
Surgery type | ||||||||||
Residual tumor status | ||||||||||
Valentini, 2011 [32] | Belgium | D + EV | Rectal cancer (II–III) | Metastasis | 5 years | 3458 | pT stage | External C statistic 0.73 (0.68–0.77); Wald statistic: p = 0.057 | Nomogram | Random split |
pN stage | ||||||||||
Surgery type | ||||||||||
Adjuvant chemotherapy | ||||||||||
Sun, 2017 [33] | China | D + EV | Rectal cancer (I–III) | Distant metastasis | 5 years | 425/97 | CRM | C statistic 0.70 (0.64–0.75)/0.71 (0.62–0.81); calibration plot | Nomogram | NA |
IMA nodes | ||||||||||
AJCC stage |
Prediction models for CRC recurrence
Author, year | Country | Study design | Population | Outcome | Prediction time horizon | Sample size (development/validation) | Predictors | Model performance (95%CI) | Model presentation | Internal validation |
---|---|---|---|---|---|---|---|---|---|---|
Hoshino, 2016 [34] | Japan | D | CRC (II) | Overall recurrence | 5 years | 4167 | Sex | C statistic 0.64; calibration plot | Nomogram | NA |
CEA | ||||||||||
Tumor location | ||||||||||
Tumor depth | ||||||||||
Lymphatic invasion | ||||||||||
Venous invasion | ||||||||||
No. of positive lymph nodes | ||||||||||
Peng, 2010 [37] | China | D | CRC (II–III) | Overall recurrence | 3 years | 95 | AJCC stage | AUC 0.75 | Formula | NA |
Genetic score | ||||||||||
Ying, 2014 [38] | China | D | CRC (I–III, curative resection) | Overall recurrence | 3 years | 205 | Tumor size | C statistic 0.810/0.890/0.802 | Nomogram | NA |
Tumor differentiation | ||||||||||
AJCC stage | ||||||||||
NLR | ||||||||||
Chemotherapy | ||||||||||
Zakaria, 2007 [39] | Japan | D | CRC (liver metastasis + hepatectomy) | Overall recurrence | 5 years | 662 | Hepatoduodenal | C statistic 0.61 (0.57–0.64)/0.58 (0.550.61) | Nomogram | NA |
Lymph node status | ||||||||||
Transfusions | ||||||||||
Primary cancer | ||||||||||
Regional lymph node | ||||||||||
No. of metastasis | ||||||||||
Tian, 2017 [36] | China | D | CRC | Overall recurrence | 3 years | 556 | Gene signature | AUC 0.921 (0.869–0.972); calibration plot | Nomogram | NA |
AJCC stage | ||||||||||
Tumor differentiation | ||||||||||
*Kim, 2018 [40] | Korea | D + IV | CRC (I) | Overall recurrence | 5 years | 1538 | Sex | C statistic 0.71; calibration plot | Nomogram | NA |
Tumor location | ||||||||||
pT stage | ||||||||||
LVI | ||||||||||
Tumor size | ||||||||||
*Miyoshi, 2016 [41] | Japan | D + EV | CRC (IV with liver and/or lung metastases) | Overall recurrence | 5 years | 113 | Preoperative CEA | C statistic 0.631 | Nomogram | NA |
Tumor location | ||||||||||
Tumor invasion | ||||||||||
Lymph node metastasis | ||||||||||
Synchronous metastatic lesions | ||||||||||
*Saso, 2018 [42] | Japan | D + EV | Colon cancer (II) | Overall recurrence | 5 years | 352/213 | CEA level | C statistic 0.675; external C statistic 0.552 | Nomogram | NA |
Tumor invasion | ||||||||||
Lymphatic invasion | ||||||||||
Venous invasion | ||||||||||
Renfro, 2014 [35] | USA | D + EV | Colon cancer (III) | Overall recurrence | 5 years | 15,995/1903 | Sex | C statistic 0.65; calibration plot | Nomogram | NA |
BMI | ||||||||||
PS | ||||||||||
T stage | ||||||||||
Lymph node ratio | ||||||||||
Grade | ||||||||||
Tumor location | ||||||||||
Treatment | ||||||||||
Hida, 2017 [43] | Japan | D | Rectal cancer (II–III) | Overall recurrence | 2 years | 792 | Tumor differentiation | AUC 0.831 | Formula | NA |
Depth | ||||||||||
Lymph node | ||||||||||
Surgery | ||||||||||
Postoperative complication | ||||||||||
Tumor height | ||||||||||
CEA | ||||||||||
Gijn, 2015 [31] | Netherlands | D + IV | Rectal cancer (tis-III) | Local recurrence | 6 years | 1823 | Distance from the anal verge | C statistic 0.787 (0.761–0.814); Hosmer–Lemeshow test: p = 0.68 | Nomogram | Cross-validation |
pT stage | ||||||||||
pN stage | ||||||||||
pM stage | ||||||||||
Surgery type | ||||||||||
Residual tumor status | ||||||||||
Radiotherapy | ||||||||||
Valentini, 2011 [32] | Belgium | D + EV | Rectal cancer (II–III) | Local recurrence | 5 years | 3458 | pT stage | External C statistic 0.68 (0.59–0.76); Wald statistic: p = 0.064 | Nomogram | Random split |
cT stage | ||||||||||
pN stage | ||||||||||
Age | ||||||||||
Concomitant chemotherapy | ||||||||||
Adjuvant chemotherapy |
Risk factor/risk predictor | Outcome evaluated in the umbrella review | Risk factor prevalence | Effect size (95% CI)a | Credibility assessment | Outcome in the risk prediction models | Effect size (95% CI)b | Model performance |
---|---|---|---|---|---|---|---|
CRC metastasis | |||||||
Histopathological risk factor | |||||||
Vascular invasion | Lymph node metastasis in pT1 CRC | 330/1731 = 19% | 2.73 (1.98–3.78) | Convincing | Lymph node metastasis in pT1 CRC | 8.45 (4.56–15.66) | AUC 0.812 (0.770–0.855); Hosmer–Lemeshow test: p = 0.737 (55) |
Lymph node metastasis in rectal cancer | 46/168 = 27% | 5.86 (0.77–44.62) | No association | ||||
Lymph node metastasis in small rectal NETs treated by local excision | 75/211 = 36% | 3.63 (0.05–268.57) | No association | ||||
Tumor budding | Lymph node metastasis in pT1 CRC | 2401/10,128 = 24% | 6.39 (5.23–7.80) | Highly suggestive | Lymph node metastasis in pT1 CRC | 1.70 (1.03–2.80) | AUC 0.812 (0.770–0.855); Hosmer–Lemeshow test: p = 0.737 (55) |
Lymph node metastasis in CRC | 1955/6739 = 29% | 4.96 (3.97–6.19) | Highly suggestive | ||||
Tumor differentiation | Lymph node metastasis in pT1 CRC | 94/2722 = 4% | 5.61 (2.90–10.83) | Suggestive | Lymph node metastasis in pT1 CRC | 11.77 (0.77–179.83) | AUC 0.90 (0.81–0.99) (49) |
Lymph node metastasis in pT1 CRC patients who underwent additional surgeries after an endoscopic resection | 122/209 = 58% | 3.77 (1.12–123.16) | No association | Synchronous bone metastasis | 1.69 (1.22–2.32) | AUC 0.903; sensitivity 0.851; specificity 0.845 (54) | |
Submucosal invasion ≥ 1 mm | Lymph node metastasis in pT1 CRC | 2389/2922 = 82% | 2.95 (1.39–6.27) | Weak | Lymph node metastasis in pT1 CRC | 2.14 (1.19–3.86) | AUC 0.812 (0.770–0.855); Hosmer–Lemeshow test: p = 0.737 (55) |
Tumor size > 1 cm | Lymph node metastasis in rectal cancer | 203/348 = 58% | 6.76 (3.25–14.04) | Highly suggestive | Peritoneal metastasis in colon cancer | 1.04 (1.00–1.09) | ROC 0.753 (57) |
Demographic risk factor | |||||||
Sex/gender | Lymph node metastasis in pT1 CRC | 465/1329 = 35% | 2.23 (0.78–6.42) | No association | Liver metastasis in CRC | NA | Sensitivity 0.74; specificity 0.62 (50) |
Distant metastasis in CRC | 1.40 (0.46–4.28) | AUC 0.80 (0.67–0.93); calibration plot (56) | |||||
CRC recurrence | |||||||
Histopathological risk factor | |||||||
Vascular invasion (intramural) | Local recurrence in CRC | 137/503 = 27% | 1.55 (0.11–21.28) | No association | Overall recurrence in stage II CRC | 1.30 (1.07–1.58) | C statistic 0.64; calibration plot (61) |
Vascular invasion (extramural) | Distant metastatic recurrence in rectal cancer | 350/1262 = 28% | 3.91 (2.61–5.86) | Highly suggestive | Overall recurrence in stage II colon cancer | 2.48 (1.22–5.57) | C statistic 0.675; external C statistic 0.552 (68) |
Anthropometric indices | |||||||
BMI (underweight) | Overall recurrence in CRC | 2752/17,636 = 16% | 1.13 (1.05–1.21) | Weak | Overall recurrence in stage III colon cancer | NA | C statistic 0.65; calibration plot (69) |
BMI (overweight) | Overall recurrence in CRC | 13,225/28,109 = 47% | 1.00 (0.96–1.05) | No association | |||
BMI (obese) | Overall recurrence in CRC | 6362/21,246 = 30% | 1.07 (1.02–1.13) | Weak |
Overlapping outcomes | Risk factor | Risk factor prevalence | Effect size (95% CI)a | Credibility assessment | Risk predictor | Effect size (95% CI)b | Model performance |
---|---|---|---|---|---|---|---|
CRC metastasis | |||||||
Lymph node metastasis in pT1 CRC | Vascular invasion | 330/1731 = 19% | 2.73 (1.98–3.78) | Convincing | Vascular invasion | 8.45 (4.56–15.66) | AUC 0.812 (0.770–0.855); Hosmer–Lemeshow test: p = 0.737 (55) |
Submucosal invasion ≥ 1 mm | 2389/2922 = 82% | 2.95 (1.39–6.27) | Weak | Submucosal invasion ≥ 1 mm | 2.14 (1.19–3.86) | ||
Tumor budding | 2401/10,128 = 24% | 6.39 (5.23–7.80) | Highly suggestive | Tumor budding | 1.70 (1.03–2.80) | ||
Histologic grade | 7.89 (2.89–21.52) | ||||||
Tumor differentiation | 94/2722 = 4% | 5.61 (2.90–10.83) | Suggestive | Tumor differentiation | 11.77 (0.77–179.83) | AUC 0.90 (0.81–0.99) (49) | |
Lymphatic invasion | 906/3347 = 27% | 6.78 (5.29–8.69) | Highly suggestive | Infiltrative growth pattern | 31.91 (2.37–428.36) | ||
Lymphovascular invasion | 340/1695 = 20% | 4.81 (3.14–7.36) | Suggestive | Lymphoid infiltrate | 28.75 (2.13–388.37) | ||
Gender | 465/1329 = 35% | 2.23 (0.78–6.42) | No association | Sessile morphology | 4.88 (0.81–29.3) | ||
Lymph node metastasis in CRC | Tumor budding | 1955/6739 = 29% | 4.96 (3.97–6.19) | Highly suggestive | CT-reported lymph node status | 1.69 (1.05–2.75) | C statistic 0.736 (0.759–0.766); Hosmer–Lemeshow test: p = 0.916 (52) |
Downregulated E-cadherin expression | 829/1573 = 53% | 0.49 (0.34–0.72) | Highly suggestive | Radiomics signature | 5.48 (3.03–9.91) | ||
Low MUC2 expression level | 613/1335 = 46% | 1.42 (1.19–1.69) | Suggestive | CEA | 1.71 (1.04–2.83) | ||
Circulating tumor cells | 797/1802 = 44% | 1.62 (1.17–2.23) | Weak | ||||
p16 protein expression | 482/800 = 60% | 0.50 (0.30–0.84) | Weak | ||||
CD147 expression | 603/815 = 74% | 1.41 (0.39–5.01) | No association | ||||
CD133 expression | 550/1629 = 34% | 1.15 (0.82–1.62) | No association | ||||
HER-2 immunohistochemical expression | 440/1289 = 34% | 1.90 (0.90–4.02) | No association | ||||
BRAF mutation | 736/1142 = 64% | 0.75 (0.49–1.14) | No association | ||||
RASSF1A promoter methylation | 100/184 = 54% | 1.61 (0.16–16.16) | No association | ||||
Hepatic metastasis in CRC | Circulating tumor cells | 103/310 = 33% | 6.38 (2.67–15.26) | Suggestive | Duke B/C | NA | Sensitivity 0.74, specificity 0.62 (50) |
ALP | NA | ||||||
Sex/gender | NA | ||||||
Distant metastasis in CRC | Downregulated E-cadherin expression | 509/1027 = 50% | 0.45 (0.23–0.91) | Weak | AJCC stage | 1.27 (0.25–6.38) | AUC 0.80 (0.67–0.93); calibration plot (56) |
Cyclin D1 overexpression | 952/1515 = 63% | 0.60 (0.36–0.99) | Weak | MiR25/MiR339 | 2.92 (0.98–8.64) | ||
β-catenin overexpression in the nucleus | 283/531 = 53% | 0.48 (0.29–0.79) | Weak | Age at surgery | 1.10 (0.20–6.03) | ||
CD147 expression | 405/538 = 75% | 2.32 (1.34E−06 to 4.03E+06) | No association | Sex/gender | 1.40 (0.46–4.28) | ||
CD133 expression | 300/1064 = 28% | 1.54 (0.39–6.09) | No association | ||||
RASSF1A promoter methylation | 153/417 = 37% | 2.57 (0.64–10.24) | No association | ||||
CRC recurrence | |||||||
Overall recurrence in CRC | Tumor budding | 802/2773 = 29% | 5.50 (3.65–8.29) | Highly suggestive | AJCC stage | NA | AUC 0.921 (0.869–0.972); calibration plot (65) |
Extranodal extension (ENE) | 376/877 = 43% | 2.07 (1.65–2.61) | Highly suggestive | Tumor differentiation | NA | ||
PTGS2 (COX-2) | 787/1516 = 52% | 2.78 (1.76–4.40) | Suggestive | Gene signature | NA | ||
Absence of peritoneal free tumor cells in pre-resection | 524/593 = 88% | 0.38 (0.16–0.91) | Weak | ||||
Absence of peritoneal free tumor cells in post-resection | 214/252 = 85% | 0.07 (0.02–0.21) | Weak | ||||
Underweight | 2752/17,636 = 16% | 1.13 (1.05–1.21) | Weak | ||||
Obese | 6362/21,246 = 30% | 1.07 (1.02–1.13) | Weak | ||||
Overweight | 13,225/28,109 = 47% | 1.00 (0.96–1.05) | No association | ||||
Diabetes | 429/4979 = 9% | 1.26 (0.70–2.30) | No association |